Use access key #2 to skip to page content.
$19.52 -0.27 (-1.36%)
8/20/2008 4:04 PM

Medicis Pharmaceutical Corp (MRX)

CAPS Rating:
*****

A specialty pharmaceutical company focused on the development and marketing of products in the United States for the treatment of dermatological, aesthetic and podiatric conditions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating MRX

Add Stock to Watchlist

What the Community Thinks

Total Members

172 Outperforms
11 Underperforms
 

All-Stars

65 Outperforms
3 Underperforms
 

Wall Street

8 Outperforms
1 Underperforms
 

Members bullish on MRX are also bullish on:

Members bearish on MRX are also bearish on:

Ticker Tags

Dermatology (7), Small Cap (1922), Biotechnology (294)
Suggest a tag

Medicis Pharmaceutical Corp At A Glance

Current Price: $19.52
Last Trade Time: 8/20/2008 4:04 PM
Open: $19.87
Previous Close: $19.79
Daily Range: $19.33 - $19.99
52-Week Range: $17.72 - $32.18
Volume: 563,858
Market Cap: $1.12B
P/E Ratio: 13.46
Compare Our Special Broker Offers!

Stock Trends

MRX VS S&P 500 (SPY)

MRX 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for MRX

More Headlines...

Top Bull Pitch

Recs

1

Medicis Pharmaceutical Corp (MRX)

Avatar Richthofen80 (96.70) Submitted: 6/22/08 12:41 PM

Pure speculation on the Liposonix acquisition. Surgery free fat removal has huge potential if FDA approves. If not, at least they get international exposure because the process is already approved in Europe.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 20 :   1 2 3 4 Next »

Recs

0

 (MRX)

Avatar APBealoth (< 20) Submitted: 8/13/08 8:34 AM : Outperform Start Price: $21.53 MRX Score: -8.53

Double Bottom, Megaphone Bottom

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MRX)

Avatar comet9 (< 20) Submitted: 7/13/08 6:37 PM : Outperform Start Price: $18.77 MRX Score: 2.25

Slowed growth in earnings due to increased expenses with LipoSonix acquisition. Whether that business takes off or not, there is very good value here.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MRX)

Avatar NASAGeek (95.54) Submitted: 6/26/08 9:21 PM : Outperform Start Price: $20.05 MRX Score: -2.00

magicformulainvesting.com screen at $153M market cap, top 25 companies on June 26, 2008

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (MRX)

Avatar Richthofen80 (96.70) Submitted: 6/22/08 12:41 PM : Outperform Start Price: $21.15 MRX Score: -4.28

Pure speculation on the Liposonix acquisition. Surgery free fat removal has huge potential if FDA approves. If not, at least they get international exposure because the process is already approved in Europe.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MRX)

Avatar healthcarevalue (96.71) Submitted: 6/20/08 12:05 AM : Outperform Start Price: $21.13 MRX Score: -3.56

1.2B market cap, price/earnings of 16 is okay, debt/equity of 0.7 is meh, but greater than 100% return on capital is nice, and the niche market and company's strategic alliances don't hurt either.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 20 :   1 2 3 4 Next »

Wall Street

Results 1 - 9 of 9  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJGreenblatt < 20 08/18/08 Outperform 1Y $20.84-6.33%-2.19%-4.15 Toggle the visibility of 60-Second Pitch and replies
TrackEveillard 93.38 09/30/07 Outperform NS $30.35-35.69%-16.38%-19.30 Toggle the visibility of 60-Second Pitch and replies
TrackMatrix 91.38 09/14/07 Underperform NS $29.90-34.72%-13.77%+20.95
TrackJPMorgan 91.13 11/08/06 Outperform NS $38.72-49.59%-7.39%-42.19
TrackDeutscheSec 87.54 10/12/06 Outperform NS $35.45-44.94%-5.87%-39.06
TrackCreditSuiss 94.39 10/05/06 Outperform NS $33.89-42.41%-5.42%-36.99
TrackRothCapital 61.70 09/29/06 Outperform NS $31.40-37.84%-4.63%-33.21
TrackRBCCapMkts 91.50 09/26/06 Outperform NS $30.35-35.69%-3.70%-31.98
TrackJimCramer 81.47 03/20/06 Outperform 3W $31.15-37.33%-2.18%-35.15

Results 1 - 9 of 9  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners